Loading
A phase 3 trial of docetaxel, cyclophosphamide, epirubicin and paclitaxel / nab-paclitaxel in triple-negative breast cancer, run by Fudan University, not yet recruiting.
Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients is a phase 3, randomised interventional study registered as NCT06795503 by Fudan University, with a registry enrolment figure of 1462 participants, started 2025-02 and due to reach its primary completion in 2028-08. Interventions recorded: Docetaxel plus cyclophosphamide; Epirubicin, cyclophosphamide plus paclitaxel. Conditions listed: Triple-negative Breast Cancer. Triple-negative eligibility wording from the registry: "Histologically confirmed invasive triple-negative breast cancer (TNBC), defined as breast cancer with estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) all determined to be negative by pathological testing". No results are recorded here; the registry entry is the source.
Shares Epirubicin, Cyclophosphamide, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Epirubicin, Cyclophosphamide, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Epirubicin, Docetaxel, Cyclophosphamide, Early triple-negative breast cancer and the tag tnbc-deep-dive.
Shares Epirubicin, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Epirubicin, Cyclophosphamide, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Epirubicin, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Paclitaxel / nab-paclitaxel and the tag tnbc-deep-dive.
Shares Epirubicin, Docetaxel, Cyclophosphamide, Early triple-negative breast cancer and the tag tnbc-deep-dive.
Shares Epirubicin, Cyclophosphamide, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.